In Western countries, where the incidence of breast cancer is high, the effectiveness of chemoprevention by inhibiting the actions of estrogen using the hormone antagonist tamoxifen, which is classified as a selective estrogen receptor modulator, or other agents has been tested, and such chemoprevention has been approved by the US Food and Drug Administration (FDA) agency. The gene discussed is ESR1; the disease is breast cancer.